MagForce AG (MF6) - Net Assets
Based on the latest financial reports, MagForce AG (MF6) has net assets worth €26.84 Million EUR (≈ $31.38 Million USD) as of December 2021. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€62.83 Million ≈ $73.45 Million USD) and total liabilities (€35.99 Million ≈ $42.07 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check MF6 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €26.84 Million |
| % of Total Assets | 42.72% |
| Annual Growth Rate | 13.91% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 76.95 |
MagForce AG - Net Assets Trend (2018–2021)
This chart illustrates how MagForce AG's net assets have evolved over time, based on quarterly financial data. See MF6 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for MagForce AG (2018–2021)
The table below shows the annual net assets of MagForce AG from 2018 to 2021. For live valuation and market cap data, see how much is MagForce AG worth.
| Year | Net Assets | Change |
|---|---|---|
| 2021-12-31 | €26.84 Million ≈ $31.38 Million |
-24.42% |
| 2020-12-31 | €35.51 Million ≈ $41.52 Million |
+141.46% |
| 2019-12-31 | €14.71 Million ≈ $17.20 Million |
-19.00% |
| 2018-12-31 | €18.16 Million ≈ $21.23 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to MagForce AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 455820800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2021)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €29.93 Million | 111.52% |
| Other Components | €53.53 Million | 199.44% |
| Total Equity | €26.84 Million | 100.00% |
MagForce AG Competitors by Market Cap
The table below lists competitors of MagForce AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Braime Group PLC
LSE:BMT
|
$122.64K |
|
Marlowe plc
LSE:MRL
|
$122.94K |
|
IQ-AI LTD. LS -01
F:5Y1
|
$123.35K |
|
Cloudbreak Discovery PLC
LSE:CDL
|
$123.87K |
|
Red Capital PLC
LSE:REDC
|
$122.43K |
|
PowerHouse Energy Group Plc
LSE:PHE
|
$122.42K |
|
DSW Capital PLC
LSE:DSW
|
$122.31K |
|
Tap Global Group Plc
LSE:TAP
|
$122.31K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MagForce AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2020 to 2021, total equity changed from 35,514,720 to 26,840,455, a change of -8,674,264 (-24.4%).
- Net loss of 10,574,258 reduced equity.
- Other factors increased equity by 1,899,994.
Equity Change Factors (2020 to 2021)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-10.57 Million | -39.4% |
| Other Changes | €1.90 Million | +7.08% |
| Total Change | €- | -24.42% |
Book Value vs Market Value Analysis
This analysis compares MagForce AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | €0.69 | €0.00 | x |
| 2019-12-31 | €0.53 | €0.00 | x |
| 2020-12-31 | €1.21 | €0.00 | x |
| 2021-12-31 | €0.90 | €0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MagForce AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -39.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3004.19%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 2.34x
- Recent ROE (-39.40%) is below the historical average (-8.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 24.00% | 6485.20% | 0.00x | 2.04x | €2.54 Million |
| 2019 | -59.36% | -1039.44% | 0.02x | 2.49x | €-10.20 Million |
| 2020 | 41.52% | 2374.12% | 0.01x | 1.85x | €11.20 Million |
| 2021 | -39.40% | -3004.19% | 0.01x | 2.34x | €-13.26 Million |
Industry Comparison
This section compares MagForce AG's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $48,854,925,736
- Average return on equity (ROE) among peers: -45.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MagForce AG (MF6) | €26.84 Million | 24.00% | 1.34x | $122.48K |
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | $12.27 Billion | 14.01% | 0.69x | $140.36K |
| BIORETEC OY (0TN) | $4.34 Million | -138.72% | 0.98x | $16.10 Million |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $464.53 Billion | 11.55% | 0.43x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $554.62 Million | 29.12% | 0.16x | $711.77 Million |
| HeraMED Limited (1I4) | $2.77 Million | -198.14% | 0.62x | $28.30 Million |
| Medtronic PLC (2M6) | $6.43 Billion | 15.30% | 0.70x | $83.04 Billion |
| Peijia Medical Limited (4WO) | $1.86 Billion | -10.94% | 0.43x | $324.05 Million |
| AVITA Medical Inc (51KB) | $20.86 Million | -118.03% | 0.23x | $172.49 Million |
| BRAINCOOL AB (5YL) | $116.23 Million | -39.24% | 0.15x | $21.56 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.75 Billion | -16.50% | 0.09x | $107.57 Million |
About MagForce AG
MagForce AG develops advanced nanomedicine for cancer therapies. It offers NanoTherm therapy system, a combination of medical devices for the treatment of solid brain tumors; NanoPlan, a software that stimulates the temperature distribution in the treatment area; NanoTherm, a magnetic ferrofluid; and NanoActivator, a magnetic field generator. MagForce AG was founded in 1997 and is headquartered i… Read more